| Literature DB >> 35321732 |
Likui Fang1, Wenfeng Yu1, Guocan Yu1, Bo Ye1, Gang Chen2.
Abstract
BACKGROUND: The effects of matrix metalloproteases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) expressions on the patients with constrictive pericarditis undergoing pericardiectomy remain unclear. This study explored the associations of MMPs and TIMPs expressions with postoperative outcomes in these patients.Entities:
Keywords: Constrictive pericarditis; MMP9; Postoperative outcomes
Mesh:
Substances:
Year: 2022 PMID: 35321732 PMCID: PMC8943958 DOI: 10.1186/s13019-022-01796-9
Source DB: PubMed Journal: J Cardiothorac Surg ISSN: 1749-8090 Impact factor: 1.637
Expressions of MMPs and TIMP1 in the constrictive pericardium based on the postoperative complications
| Variables | Postoperative complications | ||
|---|---|---|---|
| Yes (N = 10) | No (N = 12) | ||
| MMP1 | 5.99 (− 0.44–11.79) | 9.16 (2.96–13.06) | 0.539 |
| MMP2 | 2.83 (0.75–4.63) | 2.00 (0.80–3.05) | 0.080 |
| MMP9 | 5.77 (3.19–11.11) | 3.32 (2.04–4.85) | 0.002 |
| TIMP1 | 1.53 (− 1.10–2.98) | 0.81 (− 0.54–2.55) | 0.180 |
Values presented as median (range)
MMP, matrix metalloproteinase; TIMP, tissue inhibitors of matrix metalloproteinase
Fig. 1The area under the ROC curve for postoperative complications determined using the level of MMP9. ROC, receiver operating characteristic; AUC, area under the curve
Baseline characteristics of study patients based on the level of MMP9 in the constrictive pericardium
| Variables | MMP9-low group (N = 11) | MMP9-high group (N = 11) | |
|---|---|---|---|
| Gender | |||
| Male | 11 (100%) | 11 (100%) | |
| Age, years | 70 (54–80) | 73 (54–80) | 0.270 |
| Etiology | – | ||
| Tuberculosis | 11 (100%) | 11 (100%) | |
| Preoperative NYHA functional class | 0.327 | ||
| I | 2 (18.2%) | 0 (0%) | |
| II | 1 (9.1%) | 3 (27.3%) | |
| III | 8 (72.7%) | 8 (72.7%) | |
| Hypertension | 1 (9.1%) | 2 (18.2%) | 1.000 |
| Diabetes | 2 (18.2%) | 2 (18.2%) | 1.000 |
| Heart disease* | 2 (18.2%) | 4 (36.4%) | 0.635 |
| BMI, kg/m2 | 21.3 (17.3–24.8) | 21.0 (17.7–24.8) | 0.652 |
| Pulse rate, beats/min | 98 (80–112) | 90 (80–145) | 0.699 |
| Preoperative CVP, cmH2O | 23.0 (20.5–30.0) | 30.0 (20.4–42.5) | 0.065 |
| Pericardial thickness, mm | 10.7 (8.2–16.0) | 10.7 (7.0–16.0) | 0.847 |
| LVEF, % | 54.3 (50.0–56.4) | 56.0 (51.9–64.0) | 0.101 |
| CRP, mg/L | 11.7 (5.0–21.0) | 17.0 (5.0–62.5) | 0.076 |
| ESR, mm/h | 37.0 (3.0–52.0) | 37.0 (17.0–68.0) | 0.300 |
Values presented as N (percentage) for categorical variables and median (range) for continuous variables
MMP9-low was defined as the level of MMP9 < 3.67 and MMP9-high was defined as MMP9 ≥ 3.67
MMP, matrix metalloproteinase; NYHA, New York Heart Association; BMI, body mass index; CVP, central venous pressure; LVEF, left ventricular ejection fraction (measured on echocardiogram); CRP, C-reactive protein; ESR, erythrocyte sedimentation rate
*Heart disease included atrial fibrillation and coronary heart disease
Postoperative outcomes of study patients stratified by the level of MMP9 in the constrictive pericardium
| Variables | MMP9-low group (N = 11) | MMP9-high group (N = 11) | |
|---|---|---|---|
| Postoperative CVP, cmH2O | 17.0 (5.0–20.0) | 17.8 (5.0–32.0) | 0.365 |
| Postoperative intubation, h | 11 (3–132) | 28 (5–232) | 0.173 |
| Duration of using vasoactive agents, h | 0 (0–116) | 47 (0–143) | 0.114 |
| Postoperative complications | 1 (9.1%) | 9 (81.8%) | 0.002 |
| Postoperative ICU stay, days | 2 (1–5) | 4.5 (1–10) | 0.040 |
| Postoperative hospital stay, days | 18 (13–24) | 23 (13–29) | 0.043 |
| In-hospital mortality | 0 (0%) | 1 (9.1%) | 1.000 |
Values presented as median (range) for continuous variables and N (percentage) for categorical variables
MMP9-low was defined as the level of MMP9 < 3.67 and MMP9-high was defined as MMP9 ≥ 3.67
MMP, matrix metalloproteinase; CVP, central venous pressure; ICU, intensive care unit
Effect of the level of MMP9 in the constrictive pericardium on postoperative outcomes
| Groups | Postoperative complications | ||
|---|---|---|---|
| OR | 95%CI | ||
| MMP9-low group | 1 | – | – |
| MMP9-high group | 27.096 | 1.166–629.886 | 0.040 |
MMP9-low was defined as the level of MMP9 < 3.67 and MMP9-high was defined as MMP9 ≥ 3.67
MMP, matrix metalloproteinase; OR, odds ratio; CI, confidence interval